Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07550517 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

StatusRecruiting
PhasePhase 2
Started2026-08-17
View on ClinicalTrials.gov ↗

Amendment history

2026-09-23
Recruitment opened
2026-08-06
Study Status v2
Primary completion pushed: 2032-07 → 2032-08
Completion pushed: 2033-07 → 2033-08
Start date2026-07→2026-08
2026-06-22
Study Status v1
Primary completion pushed: 2032-04 → 2032-07
Completion pushed: 2033-04 → 2033-07
Start date2026-04→2026-07
2026-04-21
Original filing
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.
Trial Details
NCT Number NCT07550517
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Novartis Pharmaceuticals
Conditions High-Risk Localized Prostate Cancer
Enrollment 60 participants
Start Date 2026-08-17
Primary Completion 2032-08 (estimated)
Study Completion 2033-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-22